Profound Medical Corp. (TSE:PRN - Free Report) - Research analysts at Leede Financial issued their FY2024 earnings per share estimates for Profound Medical in a report issued on Monday, November 4th. Leede Financial analyst D. Loe anticipates that the company will post earnings per share of ($1.27) for the year. The consensus estimate for Profound Medical's current full-year earnings is ($1.90) per share. Leede Financial also issued estimates for Profound Medical's FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.14 EPS.
Profound Medical Price Performance
Shares of PRN traded up C$0.26 during trading hours on Wednesday, hitting C$11.20. 7,425 shares of the company were exchanged, compared to its average volume of 7,037. The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98. The company has a market capitalization of C$274.18 million, a PE ratio of -6.59 and a beta of 0.81. The firm has a fifty day simple moving average of C$10.81 and a 200-day simple moving average of C$11.51. Profound Medical has a one year low of C$9.55 and a one year high of C$16.00.
Profound Medical (TSE:PRN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.38). The business had revenue of C$3.06 million during the quarter, compared to analyst estimates of C$3.42 million.
Insider Activity
In other Profound Medical news, Senior Officer Rashed Osman Dewan bought 9,765 shares of the firm's stock in a transaction dated Thursday, August 15th. The stock was acquired at an average price of C$12.85 per share, with a total value of C$125,480.25. 8.62% of the stock is currently owned by company insiders.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Read More
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
